https://ir.castlebiosciences.com/news-events/press-releases/detail/268/castle-biosciences-presents-new-data-demonstrating-the-clinical-utility-and-value-of-decisiondx-scc-in-moderately-and-poorly-differentiated-cutaneous-squamous-cell-carcinoma-tumors
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of...
Study finds that DecisionDx-SCC adds clarity and confidence to risk-aligned treatment decisions, independent of clinicopathologic factors and…...
utility and valuecastlebiosciencespresentsnew